Skip Navigation


NDT Advance Access originally published online on December 2, 2005
Nephrology Dialysis Transplantation 2006 21(3):697-700; doi:10.1093/ndt/gfi304
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/3/697    most recent
gfi304v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ergün, I.
Right arrow Articles by Karatan, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ergün, I.
Right arrow Articles by Karatan, O.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Original Articles: Clinical Nephrology

The safety of gadolinium in patients with stage 3 and 4 renal failure

Ihsan Ergün1, Kenan Keven1, Irfan Uruç1, Yakup Ekmekçi1, Basol Canbakan1, Ilhan Erden2 and Oktay Karatan1

1 Department of Nephrology and 2 Department of Radiology, Ankara University School of Medicine, Ibni-Sina Hospital, Ankara, Turkey

Correspondence and offprint requests to: Ihsan Ergün, MD, Ankara University School of Medicine, Ibni Sina Hospital, Department of Nephrology, Sihhiye, 06100, Ankara, Turkey. Email: ihsanerg{at}yahoo.com, iergun{at}medicine.ankara.edu.tr

Background. Although there is a well-documented risk of acute renal failure (ARF) with the iodinated contrast agents, intravenous gadolinium-based contrast agents are considered non-nephrotoxic and have been widely used for magnetic resonance imaging (MRI). However, debate continues regarding the safety issue of gadolinium, especially in patients with kidney failure. Therefore, we aimed to evaluate the safety of gadolinium in patients with stage 3 and 4 renal failure as well as risk factors for nephrotoxicity.

Method. We retrospectively analysed 473 patients with chronic renal failure who underwent angiographic MRI procedures in our centre from February 1999 to March 2005 in whom gadolinium was used as the sole contrast agent at a dose of 0.2 ml/kg. Among them, 91 patients with stage 3 or 4 renal failure according to K/DOQI definition, who had available data in their files, were enrolled in the study. The ARF was defined as an increase of at least 0.5 mg/dl in serum creatinine level over baseline after using gadolinium.

Results. Eleven of 91 (52 males, 39 females; median age 59 years; median estimated glomerular filtration rate (eGFR) 33 ml/min/1.73 m2) patients developed ARF (12.1%). The median eGFR was lower in patients with ARF than in those who did not develop ARF. The risk factors for ARF were baseline eGFR, older age, diabetic nephropathy and low baseline haemoglobin and albumin levels. Baseline eGFR and diabetic nephropathy were determined as the independent risk factors in regression analysis.

Conclusions. An ARF can occur after gadolinium-based contrast agents in patients with moderate to severe chronic renal failure. Risk factors for ARF after gadolinium toxicity include diabetic nephropathy and low GFR.

Keywords: acute renal failure; chronic renal failure; contrast nephropathy; gadolinium


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Vasc MedHome page
G. J Dubel and T. P Murphy
The role of percutaneous revascularization for renal artery stenosis
Vascular Medicine, May 1, 2008; 13(2): 141 - 156.
[Abstract] [PDF]

Home page
 Arch OphthalmolHome page
A. Kahana, M. J. Lucarelli, A. M. Grayev, J. J. Van Buren, C. N. Burkat, and L. R. Gentry
Noninvasive Dynamic Magnetic Resonance Angiography With Time-Resolved Imaging of Contrast KineticS (TRICKS) in the Evaluation of Orbital Vascular Lesions
Arch Ophthalmol, December 1, 2007; 125(12): 1635 - 1642.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
G. T. C. Wong and M. G. Irwin
Contrast-induced nephropathy
Br. J. Anaesth., October 1, 2007; 99(4): 474 - 483.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
U. Nyman, B. Elmstahl, and P. Leander
Suggesting Gadolinium-based Contrast Media for CT in Azotemic Patients Is Not Based on Historical, Clinical, and Experimental Data
Radiology, August 1, 2007; 244(2): 622 - 623.
[Full Text] [PDF]

Home page
 RadioGraphicsHome page
G. E. Wile, J. R. Leyendecker, K. A. Krehbiel, R. B. Dyer, and R. J. Zagoria
CT and MR Imaging after Imaging-guided Thermal Ablation of Renal Neoplasms
RadioGraphics, March 1, 2007; 27(2): 325 - 339.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
B. Cheong, R. Muthupillai, M. F. Rubin, and S. D. Flamm
Normal Values for Renal Length and Volume as Measured by Magnetic Resonance Imaging
Clin. J. Am. Soc. Nephrol., January 1, 2007; 2(1): 38 - 45.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.